TB-500 dosage chart
5 mg Vial
TB-500 is dosed at 500 mcg–1 mg daily via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 1.67 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
- Typical daily range
- 500–1000 mcg once daily (gradual titration recommended).
- Easy measuring
- At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution.
Dosing schedule
| Phase | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg | 30 units (0.30 mL) |
| Weeks 3–4 | 600 mcg | 36 units (0.36 mL) |
| Weeks 5–8 | 750 mcg | 45 units (0.45 mL) |
| Weeks 9–12 | 1000 mcg | 60 units (0.60 mL) |
Reconstitution steps
- 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 2Inject slowly down the vial wall; avoid foaming.
- 3Gently swirl/roll until dissolved (do not shake).
- 4Label with date and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important Notes
Practical considerations for consistency and safety in research protocols.
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and lipohypertrophy.
- Inject slowly; wait a few seconds before withdrawing the needle to prevent backflow.
- Document daily dose, injection site, and any observations to maintain consistency.
- Regulatory Note: TB‑500 is banned by WADA for athletic use and is not FDA‑approved for human administration.
How This Works
TB‑500 represents the N‑terminal active fragment of thymosin beta‑4, specifically the heptapeptide sequence Ac‑LKKTETQ. This region is responsible for the actin‑binding and cell‑migration properties of the full thymosin molecule. Preclinical studies demonstrate that TB‑500 promotes angiogenesis, accelerates wound healing, and supports tissue regeneration by upregulating cell motility and blood vessel formation. Research in animal models shows enhanced collagen deposition and reduced healing time in injury sites treated with thymosin fragments. Recent metabolic studies suggest TB‑500 may act as a prodrug, cleaving to an active pentapeptide metabolite that drives biological activity.
Potential Benefits & Side Effects
Observations from preclinical and veterinary literature.
- Supports accelerated wound healing and tissue repair through enhanced angiogenesis and cell migration.
- May reduce inflammation and fibrosis indirectly via thymosin pathways observed in animal models.
- Generally well tolerated in veterinary studies; occasional mild injection‑site reactions (redness, tenderness) reported.
- Human safety data is limited; no large‑scale clinical trials have been completed for TB‑500 specifically.
Lifestyle Factors
Complementary strategies for optimal research outcomes.
- Maintain adequate protein intake to support tissue repair and regeneration processes.
- Combine with appropriate physical activity; avoid overtraining during injury recovery phases.
- Prioritize sleep (7–9 hours) to maximize natural recovery and repair mechanisms.
- Manage stress levels through evidence‑based practices to support overall healing.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to air dry completely.
- Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically within approved areas (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Wait 5–10 seconds after injection before withdrawing needle to prevent medication leakage.
important-note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. TB‑500 is not approved by the FDA for human use and is for research purposes only. TB‑500 is a prohibited substance in competitive sports under WADA regulations.
TB-500 dosage FAQs
How much bacteriostatic water do you use to reconstitute TB-500?
Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration. for a 5 mg Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.
What does the TB-500 dosing schedule look like?
Weeks 1–2 — 500 mcg — 30 units (0.30 mL); Weeks 3–4 — 600 mcg — 36 units (0.36 mL); Weeks 5–8 — 750 mcg — 45 units (0.45 mL); Weeks 9–12 — 1000 mcg — 60 units (0.60 mL). The full table above lists every step with matching syringe units.
What are the mixing steps for TB-500?
Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake).
How should reconstituted TB-500 be stored?
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution..
How many insulin syringe units equal a TB-500 dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is TB-500 approved for human use?
No. TB-500 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.